Pub Date : 2024-10-29eCollection Date: 2024-10-01DOI: 10.1093/ofid/ofae563
Luca Pipitò, Irene Ganci, Andrea Cicero, Alice Annalisa Medaglia, Simona D'Avenia, Edoardo Mandalà, Cinzia Calà, Paola Di Carlo, Antonio Cascio
Diagnostic algorithms for syphilis are based on serology. However, with the advent of immunosuppressive therapies, these algorithms may fail. We report a case of an individual with multiple sclerosis on treatment with ofatumumab and secondary syphilis with visual and auditory systems involvement and persistent negative treponemal and nontreponemal tests.
{"title":"A Case of Syphilis With Ocular Involvement: Persistent Negative Serology in a Patient With Multiple Sclerosis.","authors":"Luca Pipitò, Irene Ganci, Andrea Cicero, Alice Annalisa Medaglia, Simona D'Avenia, Edoardo Mandalà, Cinzia Calà, Paola Di Carlo, Antonio Cascio","doi":"10.1093/ofid/ofae563","DOIUrl":"https://doi.org/10.1093/ofid/ofae563","url":null,"abstract":"<p><p>Diagnostic algorithms for syphilis are based on serology. However, with the advent of immunosuppressive therapies, these algorithms may fail. We report a case of an individual with multiple sclerosis on treatment with ofatumumab and secondary syphilis with visual and auditory systems involvement and persistent negative treponemal and nontreponemal tests.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae563"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-29eCollection Date: 2024-10-01DOI: 10.1093/ofid/ofae593
Grace E Marx, Alyssa Beck, Cate Corey, Candace C Fuller, Nicole Haug, Jenice S Ko, Dave Martin, Alison F Hinckley
Single-dose doxycycline after high-risk tick bites can prevent Lyme disease, which disproportionately affects children. We described single-dose doxycycline dispensings in an outpatient cohort in the United States. During 2010-2020, a total of 427 105 patients received ≥1 dispensing(s); most were aged ≥65 years. Lyme disease postexposure prophylaxis may be underprescribed for some groups, including children.
{"title":"Lyme Disease Prophylaxis by Single-Dose Doxycycline in the United States, 2010-2020.","authors":"Grace E Marx, Alyssa Beck, Cate Corey, Candace C Fuller, Nicole Haug, Jenice S Ko, Dave Martin, Alison F Hinckley","doi":"10.1093/ofid/ofae593","DOIUrl":"https://doi.org/10.1093/ofid/ofae593","url":null,"abstract":"<p><p>Single-dose doxycycline after high-risk tick bites can prevent Lyme disease, which disproportionately affects children. We described single-dose doxycycline dispensings in an outpatient cohort in the United States. During 2010-2020, a total of 427 105 patients received ≥1 dispensing(s); most were aged ≥65 years. Lyme disease postexposure prophylaxis may be underprescribed for some groups, including children.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae593"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28eCollection Date: 2024-10-01DOI: 10.1093/ofid/ofae551
Kayla Gaete, Soma Dalai, Ana Cabrera, Xena Li, Prameet M Sheth, Robert A Kozak, Mia J Biondi
Background: Globally, Creutzfeldt-Jakob disease (CJD) affects one in one million people annually, but there is a paucity of recent Canadian data. This study summarizes epidemiology trends and diagnostic timelines of laboratory-confirmed CJD cases in three tertiary Ontario hospitals.
Method: Using laboratory information systems, we identified 30 patients with a laboratory-confirmed CJD diagnosis between 2012 and 2022 at three major tertiary hospitals in Ontario. Retrospective chart reviews were then completed.
Results: Patients had a mean of 2.2 hospital visits (SD, 1.2) prior to being admitted for testing. The most common symptom presentations included loss of coordination (63.3%), behavioral changes (60%), progressive mobility loss (53.4%), memory loss (50.0%), and involuntary movements (50.0%). Magnetic resonance imaging findings showed potential CJD in 76.7% of cases, and 56.7% exhibited periodic sharp wave complexes characteristic of CJD on electroencephalogram. The mean duration from symptom onset to microbiologic testing was 91 days (SD, 90.7). End-point quaking-induced conversion (EP-QuIC) testing of cerebrospinal fluid was positive in 90.0% of patients, while 83.3% tested positive for 14-3-3 on enzyme-linked immunosorbent assay. Elevated cerebrospinal fluid 14-3-3 levels significantly correlated with shorter duration from symptom onset to death (R2 = 0.71, F = 19.55, P = .0022). Post-diagnosis, 46.7% of patients were discharged home, 16.6% were transferred to external palliative care or hospice facilities, and 36.7% died during admission. The mean time from symptom onset to death was 121 days (SD, 120.7), and from diagnosis to death 35 days (SD, 83.9).
Conclusions: This study highlights the importance of early CJD consideration and laboratory testing when appropriate neurologic symptoms are present.
{"title":"Characterization of Laboratory-Confirmed Creutzfeldt-Jakob Disease From 3 Ontario Tertiary Care Centers Between 2012 and 2022: A Retrospective Cohort Study.","authors":"Kayla Gaete, Soma Dalai, Ana Cabrera, Xena Li, Prameet M Sheth, Robert A Kozak, Mia J Biondi","doi":"10.1093/ofid/ofae551","DOIUrl":"10.1093/ofid/ofae551","url":null,"abstract":"<p><strong>Background: </strong>Globally, Creutzfeldt-Jakob disease (CJD) affects one in one million people annually, but there is a paucity of recent Canadian data. This study summarizes epidemiology trends and diagnostic timelines of laboratory-confirmed CJD cases in three tertiary Ontario hospitals.</p><p><strong>Method: </strong>Using laboratory information systems, we identified 30 patients with a laboratory-confirmed CJD diagnosis between 2012 and 2022 at three major tertiary hospitals in Ontario. Retrospective chart reviews were then completed.</p><p><strong>Results: </strong>Patients had a mean of 2.2 hospital visits (SD, 1.2) prior to being admitted for testing. The most common symptom presentations included loss of coordination (63.3%), behavioral changes (60%), progressive mobility loss (53.4%), memory loss (50.0%), and involuntary movements (50.0%). Magnetic resonance imaging findings showed potential CJD in 76.7% of cases, and 56.7% exhibited periodic sharp wave complexes characteristic of CJD on electroencephalogram. The mean duration from symptom onset to microbiologic testing was 91 days (SD, 90.7). End-point quaking-induced conversion (EP-QuIC) testing of cerebrospinal fluid was positive in 90.0% of patients, while 83.3% tested positive for 14-3-3 on enzyme-linked immunosorbent assay. Elevated cerebrospinal fluid 14-3-3 levels significantly correlated with shorter duration from symptom onset to death (<i>R</i> <sup>2</sup> = 0.71, <i>F</i> = 19.55, <i>P</i> = .0022). Post-diagnosis, 46.7% of patients were discharged home, 16.6% were transferred to external palliative care or hospice facilities, and 36.7% died during admission. The mean time from symptom onset to death was 121 days (SD, 120.7), and from diagnosis to death 35 days (SD, 83.9).</p><p><strong>Conclusions: </strong>This study highlights the importance of early CJD consideration and laboratory testing when appropriate neurologic symptoms are present.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae551"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28eCollection Date: 2024-11-01DOI: 10.1093/ofid/ofae644
Shaoming Xiao, Wei Zhou, Ryan Caldwell, Slade Decker, Julia Oh, Aaron M Milstone
The neonatal nasal microbiota may help protect neonates in the neonatal intensive care unit from pathogen colonization and infection. This preliminary study characterized the biodiversity of nasal microbiota comparing neonates in the neonatal intensive care unit and their mothers, highlighting the potential of strain sharing between mother-neonate pairs.
{"title":"Association of Neonatal and Maternal Nasal Microbiome Among Neonates in the Intensive Care Unit.","authors":"Shaoming Xiao, Wei Zhou, Ryan Caldwell, Slade Decker, Julia Oh, Aaron M Milstone","doi":"10.1093/ofid/ofae644","DOIUrl":"10.1093/ofid/ofae644","url":null,"abstract":"<p><p>The neonatal nasal microbiota may help protect neonates in the neonatal intensive care unit from pathogen colonization and infection. This preliminary study characterized the biodiversity of nasal microbiota comparing neonates in the neonatal intensive care unit and their mothers, highlighting the potential of strain sharing between mother-neonate pairs.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae644"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28eCollection Date: 2024-10-01DOI: 10.1093/ofid/ofae568
Itai M Magodoro, Aloice Aluoch, Brian Claggett, Moffat J Nyirenda, Mark J Siedner, Katalina A Wilkinson, Robert J Wilkinson, Ntobeko A B Ntusi
Background: Type 2 diabetes mellitus (T2DM) may be a long-term sequela of infection with Mycobacterium tuberculosis (Mtb) by mechanisms that remain to be fully explained. We evaluated the association between Mtb sensitization and T2DM and, via mediation analysis, the extent to which it is mediated by insulin resistance and/or β-cell failure.
Methods: Adults were assessed for T2DM by fasting plasma glucose, 2-hour oral glucose tolerance testing, and hemoglobin A1c; β-cell dysfunction and insulin resistance by homoeostasis model assessment 2; and Mtb sensitization by tuberculin skin testing. Associations between Mtb sensitization and T2DM were modeled with probit regression and decomposed into indirect effects of β-cell dysfunction and insulin resistance. Analyses were adjusted for sociodemographic, behavioral, and clinical characteristics.
Results: We included 1843 adults. Individuals with Mtb sensitization were older than those without Mtb (median [IQR], 54 [39-64] vs 47 [33-62] years). As compared with being uninfected, Mtb sensitization was associated with T2DM (adjusted absolute risk difference, 9.34% [95% CI, 2.38%-15.0%]; P < .001) and increased insulin resistance (adjusted median difference, 0.16 [95% CI, .03-.29]; P = .014) but not β-cell dysfunction (adjusted median difference, -3.1 [95% CI, -10.4 to 4.3]; P = .42). In mediation analyses, insulin resistance mediated 18.3% (95% CI, 3.29%-36.0%; P = .020) of the total effect of the association between Mtb sensitization and T2DM.
Conclusions: Definitive prospective studies examining incident T2DM following tuberculosis are warranted. Notwithstanding, our findings suggest that exposure to Mtb may be a novel risk factor for T2DM, likely driven by an increase in insulin resistance.
背景:2型糖尿病(T2DM)可能是结核分枝杆菌(Mtb)感染的长期后遗症,其机制尚待全面解释。我们评估了Mtb致敏与T2DM之间的关联,并通过中介分析评估了胰岛素抵抗和/或β细胞衰竭在多大程度上介导了这种关联:通过空腹血浆葡萄糖、2 小时口服葡萄糖耐量试验和血红蛋白 A1c 对成人进行 T2DM 评估;通过同源平衡模型评估 2 对 β 细胞功能障碍和胰岛素抵抗进行评估;通过结核菌素皮肤试验对 Mtb 敏化进行评估。Mtb致敏与T2DM之间的关系用probit回归建模,并分解为β细胞功能障碍和胰岛素抵抗的间接效应。分析对社会人口学、行为学和临床特征进行了调整:我们纳入了 1843 名成年人。Mtb致敏者的年龄大于未感染Mtb者(中位数[IQR],54 [39-64] vs 47 [33-62]岁)。与未感染者相比,Mtb致敏与T2DM(调整后绝对风险差异,9.34% [95% CI, 2.38%-15.0%]; P < .001)和胰岛素抵抗增加(调整后中位差异,0.16 [95% CI, .03-.29]; P = .014)相关,但与β细胞功能障碍无关(调整后中位差异,-3.1 [95% CI, -10.4 to 4.3]; P = .42)。在中介分析中,胰岛素抵抗介导了Mtb致敏与T2DM关系总效应的18.3% (95% CI, 3.29%-36.0%; P = .020):结论:有必要对结核病后发生的 T2DM 进行明确的前瞻性研究。尽管如此,我们的研究结果表明,暴露于Mtb可能是T2DM的一个新的风险因素,其驱动因素可能是胰岛素抵抗的增加。
{"title":"Association Between <i>Mycobacterium tuberculosis</i> Sensitization and Insulin Resistance Among US Adults Screened for Type 2 Diabetes Mellitus.","authors":"Itai M Magodoro, Aloice Aluoch, Brian Claggett, Moffat J Nyirenda, Mark J Siedner, Katalina A Wilkinson, Robert J Wilkinson, Ntobeko A B Ntusi","doi":"10.1093/ofid/ofae568","DOIUrl":"10.1093/ofid/ofae568","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) may be a long-term sequela of infection with <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) by mechanisms that remain to be fully explained. We evaluated the association between <i>Mtb</i> sensitization and T2DM and, via mediation analysis, the extent to which it is mediated by insulin resistance and/or β-cell failure.</p><p><strong>Methods: </strong>Adults were assessed for T2DM by fasting plasma glucose, 2-hour oral glucose tolerance testing, and hemoglobin A<sub>1c</sub>; β-cell dysfunction and insulin resistance by homoeostasis model assessment 2; and <i>Mtb</i> sensitization by tuberculin skin testing. Associations between <i>Mtb</i> sensitization and T2DM were modeled with probit regression and decomposed into indirect effects of β-cell dysfunction and insulin resistance. Analyses were adjusted for sociodemographic, behavioral, and clinical characteristics.</p><p><strong>Results: </strong>We included 1843 adults. Individuals with <i>Mtb</i> sensitization were older than those without <i>Mtb</i> (median [IQR], 54 [39-64] vs 47 [33-62] years). As compared with being uninfected, <i>Mtb</i> sensitization was associated with T2DM (adjusted absolute risk difference, 9.34% [95% CI, 2.38%-15.0%]; <i>P</i> < .001) and increased insulin resistance (adjusted median difference, 0.16 [95% CI, .03-.29]; <i>P</i> = .014) but not β-cell dysfunction (adjusted median difference, -3.1 [95% CI, -10.4 to 4.3]; <i>P</i> = .42). In mediation analyses, insulin resistance mediated 18.3% (95% CI, 3.29%-36.0%; <i>P</i> = .020) of the total effect of the association between <i>Mtb</i> sensitization and T2DM.</p><p><strong>Conclusions: </strong>Definitive prospective studies examining incident T2DM following tuberculosis are warranted. Notwithstanding, our findings suggest that exposure to <i>Mtb</i> may be a novel risk factor for T2DM, likely driven by an increase in insulin resistance.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 10","pages":"ofae568"},"PeriodicalIF":3.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-25eCollection Date: 2024-11-01DOI: 10.1093/ofid/ofae641
Wesley D Kufel, Kathleen D Hanrahan, Robert W Seabury, Katie A Parsels, Jason C Gallagher, Conan MacDougall, Elizabeth W Covington, Elias B Chahine, Rachel S Britt, Jeffrey M Steele
Background: It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses.
Methods: The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0-10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables.
Results: SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4-9), 5 (3-8), and 8 (4-10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317-.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758-.870), 0.745 (95% CI, .656-.816), and 0.833 (95% CI, .775-.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful.
Conclusions: Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.
背景:目前尚不清楚 ChatGPT 是否能高质量地回答传染病(ID)药物治疗问题。本研究对 ID 药剂师主题专家(SMEs)进行了调查,以评估 ChatGPT 3.5 版(GPT-3.5)回复的质量:主要结果是 SME 评级认为有用的 GPT-3.5 回答的百分比。次要结果是中小企业对正确性、完整性和安全性的评分。评分定义基于文献综述。在 GPT-3.5 中输入了 100 个 ID 药物治疗问题,没有自定义说明或额外提示,并记录了回复。针对正确性、完整性和安全性制定了 0-10 级评分表,并对评分者之间的可靠性进行了验证。连续变量和分类变量分别通过平均测量类内相关系数和弗莱斯多变量卡帕评估研究者之间的可靠性。通过 Kruskal-Wallis 检验和卡方检验对中小型企业的连续变量和分类变量进行比较:中小型企业认为 41.8%的答复有用。正确性、完整性和安全性的评分中位数(IQR)分别为 7(4-9)、5(3-8)和 8(4-10)。有用性的弗莱克斯多方卡帕值为 0.379(95% CI,.317-.441),表明一致性尚可;正确性、完整性和安全性的类内相关系数分别为 0.820(95% CI,.758-.870)、0.745(95% CI,.656-.816)和 0.833(95% CI,.775-.880),表明至少基本一致。在被认为有用的回答百分比方面,中小企业的回答没有明显差异:结论:中小型企业认为有用的 GPT-3.5 答复不到 50%。大多数答复被认为是正确和安全的,但往往不完整,这表明 GPT-3.5 答复可能无法取代 ID 药剂师的答复。
{"title":"Let's Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions?","authors":"Wesley D Kufel, Kathleen D Hanrahan, Robert W Seabury, Katie A Parsels, Jason C Gallagher, Conan MacDougall, Elizabeth W Covington, Elias B Chahine, Rachel S Britt, Jeffrey M Steele","doi":"10.1093/ofid/ofae641","DOIUrl":"https://doi.org/10.1093/ofid/ofae641","url":null,"abstract":"<p><strong>Background: </strong>It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses.</p><p><strong>Methods: </strong>The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0-10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables.</p><p><strong>Results: </strong>SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4-9), 5 (3-8), and 8 (4-10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317-.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758-.870), 0.745 (95% CI, .656-.816), and 0.833 (95% CI, .775-.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful.</p><p><strong>Conclusions: </strong>Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae641"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: A serum-free, highly purified Vero rabies vaccine-next generation (PVRV-NG2) is under development. We conducted a phase III trial to describe the safety and immunogenicity profile of PVRV-NG2 compared with those of licensed purified Vero rabies vaccine (PVRV) in a simulated rabies postexposure prophylaxis (PEP) Zagreb regimen in Thailand.
Methods: Healthy adults aged ≥18 years (n = 201) were randomized in a 2:1 ratio to receive PVRV-NG2 or PVRV in a rabies PEP Zagreb (days 0, 7, 21 [2-1-1]) regimen, with concomitant human rabies immunoglobulin (HRIG) at day 0. Immunogenicity end points included the proportion of participants with rabies virus-neutralizing antibody (RVNA) titers ≥0.5 IU/mL at days 0, 14, and 35. Safety outcomes were also assessed.
Results: A total of 199 participants completed the study (PVRV-NG2 n = 133, PVRV n = 66). In the PVRV-NG2 group and PVRV group, respectively, 91.0% (95% CI, 84.1%-95.6%) and 94.6% (95% CI, 85.1%-98.9%) had RVNA titers ≥0.5 IU/mL at day 14, increasing to 100% (95% CI, 96.8%-100%) and 100% (95% CI, 93.5%-100%) by day 35. The vaccines had similar safety profiles, and there were no safety concerns.
Conclusions: PVRV-NG2 showed acceptable safety and immunogenicity profiles when co-administered with HRIG in a simulated PEP Zagreb regimen in healthy adults in Thailand.
背景:一种无血清、高度纯化的下一代 Vero 狂犬病疫苗(PVRV-NG2)正在开发中。我们在泰国进行了一项 III 期试验,在模拟狂犬病暴露后预防 (PEP) 的萨格勒布方案中,比较 PVRV-NG2 与已获许可的纯化 Vero 狂犬病疫苗 (PVRV) 的安全性和免疫原性。方法:年龄≥18 岁的健康成人(n = 201)按 2:1 的比例随机接受 PVRV-NG2 或 PVRV 的狂犬病 PEP 萨格勒布方案(第 0、7、21 [2-1-1]天),第 0 天同时注射人狂犬病免疫球蛋白 (HRIG)。此外还评估了安全性结果:共有 199 名参与者完成了研究(PVRV-NG2 n = 133,PVRV n = 66)。在PVRV-NG2组和PVRV组中,第14天RVNA滴度≥0.5 IU/mL的分别为91.0%(95% CI,84.1%-95.6%)和94.6%(95% CI,85.1%-98.9%),第35天增至100%(95% CI,96.8%-100%)和100%(95% CI,93.5%-100%)。两种疫苗的安全性相似,没有安全性问题:结论:PVRV-NG2 与 HRIG 共同用于泰国健康成人的模拟 PEP Zagreb 方案时,显示出了可接受的安全性和免疫原性。
{"title":"Randomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand.","authors":"Danaya Chansinghakul, Terapong Tantawichien, Kriengsak Limkittikul, Winai Ratanasuwan, Yuancheng Wang, Celine Petit, Francoise Guinet-Morlot, Carina Frago, Andrea-Clemencia Pineda-Peña","doi":"10.1093/ofid/ofae633","DOIUrl":"10.1093/ofid/ofae633","url":null,"abstract":"<p><strong>Background: </strong>A serum-free, highly purified Vero rabies vaccine-next generation (PVRV-NG2) is under development. We conducted a phase III trial to describe the safety and immunogenicity profile of PVRV-NG2 compared with those of licensed purified Vero rabies vaccine (PVRV) in a simulated rabies postexposure prophylaxis (PEP) Zagreb regimen in Thailand.</p><p><strong>Methods: </strong>Healthy adults aged ≥18 years (n = 201) were randomized in a 2:1 ratio to receive PVRV-NG2 or PVRV in a rabies PEP Zagreb (days 0, 7, 21 [2-1-1]) regimen, with concomitant human rabies immunoglobulin (HRIG) at day 0. Immunogenicity end points included the proportion of participants with rabies virus-neutralizing antibody (RVNA) titers ≥0.5 IU/mL at days 0, 14, and 35. Safety outcomes were also assessed.</p><p><strong>Results: </strong>A total of 199 participants completed the study (PVRV-NG2 n = 133, PVRV n = 66). In the PVRV-NG2 group and PVRV group, respectively, 91.0% (95% CI, 84.1%-95.6%) and 94.6% (95% CI, 85.1%-98.9%) had RVNA titers ≥0.5 IU/mL at day 14, increasing to 100% (95% CI, 96.8%-100%) and 100% (95% CI, 93.5%-100%) by day 35. The vaccines had similar safety profiles, and there were no safety concerns.</p><p><strong>Conclusions: </strong>PVRV-NG2 showed acceptable safety and immunogenicity profiles when co-administered with HRIG in a simulated PEP Zagreb regimen in healthy adults in Thailand.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae633"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-25eCollection Date: 2024-11-01DOI: 10.1093/ofid/ofae634
Ambaru Jacinta Ojia, Sophie E Lyon, Jane Francis Birungi, Catherine Owomugisha, Rose Muhindo, Semei Buwambaza Sekitene, Christopher C Moore, Edwin Nuwagira
Background: Little is known about outcomes from cancer chemotherapy--associated infections in sub-Saharan Africa. Accordingly, among patients with cancer admitted with postchemotherapy infection in Mbarara, Uganda, we aimed to determine (1) the 30-day case fatality rate, (2) factors associated with mortality rate, and (3) clinical risk score performance.
Methods: We enrolled participants aged ≥18 years if they (1) received cancer chemotherapy within the past 30 days, (2) were admitted to the oncology ward, and (3) were prescribed intravenous antibiotics. We used Cox proportional hazards regression to determine predictors of death at 30 days and calculated the area under the receiver operating characteristic curve (AUC) for each clinical risk score.
Results: Among 150 participants, 67 (45%) were female, and the median (interquartile range) age was 56 (43-66) years. Esophageal cancer (18%) and pneumonia (42%) were the most common cancer and infection, respectively. Death occurred within 30 days in 63 participants (42%). Quick Sequential Organ Failure Assessment (qSOFA) score ≥2 (adjusted hazard ratio, 2.51 [95% confidence interval, 1.42-4.44]; P = .001), and Universal Vital Assessment (UVA) score >4 (2.13 [.08-4.18, P = .03) were independently associated with death at 30 days. An Eastern Cooperative Oncology Group (ECOG) score ≥3 was similarly independently associated with death at 30 days in the qSOFA and UVA models. The AUCs for qSOFA and UVA scores were 0.70 (95% confidence interval, .63-.79) and 0.72 (.64-.80), respectively.
Conclusions: In participants with postchemotherapy infection in Mbarara, Uganda, the case fatality rate was high. ECOG, qSOFA, and UVA scores were associated with death at 30 days.
{"title":"Factors Associated With Death at 30 Days and Evaluation of Clinical Risk Scores Among Patients With Cancer Admitted With Postchemotherapy Infection in Uganda: A Prospective Cohort Study.","authors":"Ambaru Jacinta Ojia, Sophie E Lyon, Jane Francis Birungi, Catherine Owomugisha, Rose Muhindo, Semei Buwambaza Sekitene, Christopher C Moore, Edwin Nuwagira","doi":"10.1093/ofid/ofae634","DOIUrl":"10.1093/ofid/ofae634","url":null,"abstract":"<p><strong>Background: </strong>Little is known about outcomes from cancer chemotherapy--associated infections in sub-Saharan Africa. Accordingly, among patients with cancer admitted with postchemotherapy infection in Mbarara, Uganda, we aimed to determine (1) the 30-day case fatality rate, (2) factors associated with mortality rate, and (3) clinical risk score performance.</p><p><strong>Methods: </strong>We enrolled participants aged ≥18 years if they (1) received cancer chemotherapy within the past 30 days, (2) were admitted to the oncology ward, and (3) were prescribed intravenous antibiotics. We used Cox proportional hazards regression to determine predictors of death at 30 days and calculated the area under the receiver operating characteristic curve (AUC) for each clinical risk score.</p><p><strong>Results: </strong>Among 150 participants, 67 (45%) were female, and the median (interquartile range) age was 56 (43-66) years. Esophageal cancer (18%) and pneumonia (42%) were the most common cancer and infection, respectively. Death occurred within 30 days in 63 participants (42%). Quick Sequential Organ Failure Assessment (qSOFA) score ≥2 (adjusted hazard ratio, 2.51 [95% confidence interval, 1.42-4.44]; <i>P</i> = .001), and Universal Vital Assessment (UVA) score >4 (2.13 [.08-4.18, <i>P</i> = .03) were independently associated with death at 30 days. An Eastern Cooperative Oncology Group (ECOG) score ≥3 was similarly independently associated with death at 30 days in the qSOFA and UVA models. The AUCs for qSOFA and UVA scores were 0.70 (95% confidence interval, .63-.79) and 0.72 (.64-.80), respectively.</p><p><strong>Conclusions: </strong>In participants with postchemotherapy infection in Mbarara, Uganda, the case fatality rate was high. ECOG, qSOFA, and UVA scores were associated with death at 30 days.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae634"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatitis B Triple Panel Testing Implementation in the Obstetric Care Setting: Unique Predictors of Hepatitis B Virus Vaccine Immunity, Exposure, and Positivity.","authors":"Natalia Schmidt, Jeanette Rios, Lauren Alpert, Anna Mageras, Whitney Lieb, Tatyana Kushner","doi":"10.1093/ofid/ofae632","DOIUrl":"10.1093/ofid/ofae632","url":null,"abstract":"","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae632"},"PeriodicalIF":3.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-23eCollection Date: 2024-11-01DOI: 10.1093/ofid/ofae637
Isin Y Comba, John C O'Horo, Joel E Gordon, Yngve Falck-Ytter, Matthew M Moore, Rebecca L Morgan, Reem A Mustafa, Adarsh Bhimraj
Background: The Grading Recommendations, Assessment, Development, and Evaluations (GRADE) framework is widely applied in clinical guidelines to facilitate transparent evidence evaluation. While developing Infectious Diseases Society of America (IDSA) guidelines on the management of patients with coronavirus disease 2019 (COVID-19), panel members suggested developing and implementing a visual aid to enable quicker identification of key information by providers at bedside seeking guidance.
Methods: We conducted a mixed-methods study evaluating the usability of a newly designed infographic/icon using a survey and focus groups. The survey incorporated a simulated COVID-19 IDSA guideline with and without the icon, followed by comprehension questions. Focus group discussions provided qualitative feedback on the GRADE methodology and icon usability.
Results: The survey was returned by 289 health care providers. There was no statistical difference in the correct response rates between icon-aided and non-icon-aided guideline questions (McNemar's chi-square test, P > .1 for both questions). Interactions with the icon notably increased the time taken and number of clicks required to respond to the first question (Wilcoxon signed-rank test, P < .01). In contrast, response time did not differ between versions for the second question (P = .38). Most subjects (85%) indicated that the icon improved the readability of the guidelines. A focus group follow-up suggested alternative designs for the icon.
Conclusions: This study highlights the promise of iconography in clinical guidelines, although the specific icons tested did not measurably improve usability metrics. Future research should focus on icon design and testing within a formal usability framework, considering the impact of GRADE language on user experience.
{"title":"Beyond Words: Enhancing Clinical Guideline Comprehension With Icons.","authors":"Isin Y Comba, John C O'Horo, Joel E Gordon, Yngve Falck-Ytter, Matthew M Moore, Rebecca L Morgan, Reem A Mustafa, Adarsh Bhimraj","doi":"10.1093/ofid/ofae637","DOIUrl":"https://doi.org/10.1093/ofid/ofae637","url":null,"abstract":"<p><strong>Background: </strong>The Grading Recommendations, Assessment, Development, and Evaluations (GRADE) framework is widely applied in clinical guidelines to facilitate transparent evidence evaluation. While developing Infectious Diseases Society of America (IDSA) guidelines on the management of patients with coronavirus disease 2019 (COVID-19), panel members suggested developing and implementing a visual aid to enable quicker identification of key information by providers at bedside seeking guidance.</p><p><strong>Methods: </strong>We conducted a mixed-methods study evaluating the usability of a newly designed infographic/icon using a survey and focus groups. The survey incorporated a simulated COVID-19 IDSA guideline with and without the icon, followed by comprehension questions. Focus group discussions provided qualitative feedback on the GRADE methodology and icon usability.</p><p><strong>Results: </strong>The survey was returned by 289 health care providers. There was no statistical difference in the correct response rates between icon-aided and non-icon-aided guideline questions (McNemar's chi-square test, <i>P</i> > .1 for both questions). Interactions with the icon notably increased the time taken and number of clicks required to respond to the first question (Wilcoxon signed-rank test, <i>P</i> < .01). In contrast, response time did not differ between versions for the second question (<i>P</i> = .38). Most subjects (85%) indicated that the icon improved the readability of the guidelines. A focus group follow-up suggested alternative designs for the icon.</p><p><strong>Conclusions: </strong>This study highlights the promise of iconography in clinical guidelines, although the specific icons tested did not measurably improve usability metrics. Future research should focus on icon design and testing within a formal usability framework, considering the impact of GRADE language on user experience.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae637"},"PeriodicalIF":3.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}